Process of transition Sample Clauses
Process of transition. The transitional arrangements apply with effect from 1 April 2021. Eligible doctors will be entitled to express their interest to transfer to the TCS during a six-month choice window from 1 April 2021 to 30 September 2021. Where the doctor wishes to do so, they will enter into the process set out below.
a. On or shortly after the 1 April 2021, employing organisations will write to eligible doctors to, a) confirm that the doctor is eligible to transfer to these TCS and b) invite an expression of interest.
b. The eligible doctor shall have until 30 September 2021 (six months from the 1 April) to confirm that they would be interested in transferring to these TCS (“an expression of interest”). An expression of interest shall not be legally binding nor shall it oblige the doctor to transfer to these TCS, but it shall signify that the doctor wishes to commence the job planning process in good faith and in the expectation of transferring.
c. The employing organisation and the doctor shall then undertake the job planning process as set out in Schedule 4 of the TCS. Following the completion of this process the employing organisation will offer the doctor a job plan and salary package in writing (“the offer”).
d. Following such an offer, the doctor has 21 days within which to accept or decline the offer in writing.
e. Where it has not been possible to agree a job plan the doctor shall have access to the provisions for mediation and appeal as set out in Schedule 5 prior to making a final decision on transferring to these TCS.
a. On or shortly after the 1 April 2021, employing organisations will write to eligible doctors to, a) confirm that the doctor is eligible to transfer to these TCS and b) invite an expression of interest.
b. The eligible doctor shall have until 30 September 2021 (six months from the 1 April) to confirm that they would be interested in transferring to these TCS (“an expression of interest”). An expression of interest shall not be legally binding nor shall it oblige the doctor to transfer to these TCS but it shall signify that the doctor wishes to commence the job planning process in good faith and in the expectation of transferring.
c. The doctor will need to evidence that they meet they meet the entry requirements for the specialist grade detailed in Section 1.2 of this document.
d. If the doctor meets the criteria, the employing organisation and the doctor shall then undertake the job planning process as set out in Schedule 4. Following the com...
Process of transition. In the event Amgen provides a notice to Purchaser of the intent to transition the manufacturing (either in the entirety, only the formulation, fill and finish manufacturing activities, or only the manufacture of Bulk Drug Substance (if Amgen has previously transitioned the formulation, fill and finish manufacturing activities)) of Drug Product (such manufacturing activities to be transitioned, the “Transitioned Manufacturing”), to an alternate source pursuant to Sections 2.9 (Changes to Manufacturing), 2.14.3 (Bulk Drug Substance), 7.4 (Termination by Amgen for Discontinuation) or 7.4 (Change of Control), then Amgen and Purchaser shall cooperate to transition the Transitioned Manufacturing to a mutually acceptable Third-Party manufacturer. Purchaser shall contract directly with the Third-Party manufacturer and shall be responsible for the Transitioned Manufacturing of Drug Product for Purchaser, its Affiliates and sublicensees for Licensee Indications in the Territory. Amgen shall cooperate to provide to such Third-Party manufacturer, under obligations of confidentiality, [*] such Transitioned Manufacturing of Drug Product for Purchaser in the Licensee Indications in the Territory. Amgen shall also, in connection therewith, grant to such Third-Party manufacturer a non-exclusive license to use such manufacturing technology solely for the purposes of performing the Transitioned Manufacturing of Drug Product for Purchaser for the Licensee Indications in the Territory. Purchaser shall be solely responsible for all costs associated with the transition to such Third-Party manufacturer (including payment at the FTE Rate for hours of [*] provided by Amgen) and all costs associated with the purchase of Drug Product from such Third-Party manufacturer. Amgen shall have no responsibility to Purchaser for Purchaser’s supply of Drug Product to be provided by a Third-Party manufacturer pursuant to this Section 2.14 (Alternate Supply).
Process of transition. In the event that either party hereto elects to terminate this Agreement, the parties shall negotiate an orderly process of transition culminating in a written Transition Plan in accordance with the provisions of Attachment I hereto. The parties will meet within thirty (30) days of a party's election to terminate this Agreement and thereafter as set out in Attachment I. The parties' obligations under this Section 28.3 shall survive the termination or expiration of this Agreement.